Mycotopia Therapies, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Aibotics, Inc. reported a net loss of $1.61 million for the nine months ended September 30, 2025, with significant liquidity challenges and a working capital deficit.
Aibotics, Inc. reported a widening net loss and significant working capital deficit for Q2 2025, raising substantial doubt about its ability to continue as a going concern.
AIBiotics Therapies reports its Q1 2025 results, highlighting the emergence of revenue alongside continued net losses and concerns about its ability to operate as a going concern.
Mycotopia Therapies reports a net loss of $1.36 million for the nine months ended September 30, 2024, and expresses substantial doubt about its ability to continue as a going concern.
Mycotopia Therapies' Q2 2024 filing reveals a widening net loss and a working capital deficit, raising substantial doubt about the company's ability to continue as a going concern.
Mycotopia Therapies reports increased net loss and a growing working capital deficit in its Q1 2024 results, raising substantial doubt about its ability to continue as a going concern.